Home・Listă Acțiuni・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Închisă

SectorSănătate

192.57 5.65

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

181

Maxim

194

Indicatori cheie
By Trading Economics
Venit	-89M -454M
EPS	-2.29
Angajați	883
EBITDA	-89M -437M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+10.23% upside

Dividende
By Acuity
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	8.5B 40B
Deschiderea anterioară	186.92
Închiderea anterioară	192.57

Sentimentul știrilor

By Acuity

67%

33%

291 / 340 Clasament în Healthcare

REVOLUTION Medicines Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 iul. 2026, 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 iul. 2026, 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 iul. 2026, 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 iul. 2026, 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 iul. 2026, 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 iul. 2026, 18:26 UTC

Social Media

News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 iul. 2026, 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

21 iul. 2026, 17:16 UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

20 iul. 2026, 17:31 UTC

Social Media

News

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.

Comparație

Modificare preț

REVOLUTION Medicines Inc Așteptări

Obiectiv de preț

By TipRanks

10.23% sus

Prognoză pe 12 luni

Medie 201.12 USD 10.23%

Maxim 263 USD

Minim 151 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruREVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 19 analiști care au acordat evaluări ale acțiunilor REVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

291 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.